March, 2020 | Lao Tribune

Monthly Archives March 2020

Philips to postpone its Capital Markets Day to the fourth quarter of ...

March 31, 2020 Amsterdam, the Netherlands – In connection with the coronavirus disease (COVID-19) outbreak and related precautionary measures, Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it will postpone its Capital Markets Day – which was scheduled to take place in London (UK) on May 13, 2020 –  to the […]Read More

Årsrapport 2019

Herlev 31. marts 2020 Selskabsmeddelelse 10/2020 Årsregnskab 2019 + frasalg af aktivitet: SIG A/S præsterede i 2019 et tilfredsstillende EBIT resultat, som samtidig blev afsættet til frasalget af den danske aktivitet med closing pr. 31/12-2019. Frasalget var samtidig en tilfredsstillende eksekvering af strategien fra juni 2018. Omsætningen blev på 324 mio. DKK og EBIT DKK […]Read More

SweeGen Accelerates Global Expansion with New Food and Beverage ...

New centers enable deep collaboration with global and regional customers on sugar reduction and taste innovations Rancho Santa Margarita, Calif., March 30, 2020 (GLOBE NEWSWIRE) — Global food and beverage manufacturers can now easily create and collaborate on exploring sugar reduction solutions with SweeGen in its newly launched Food and Beverage Application Centers located in […]Read More

EdtechX Holdings (NASDAQ:EDTX) and Meten International Announce ...

Meten EdTechX London, March 30, 2020 (GLOBE NEWSWIRE) — EdtechX Holdings (NASDAQ:EDTX) and Meten International Announce Successful Merger Closing and Capital Raise EdtechX Holdings Acquisition Corp. (“EdtechX”) (Nasdaq: EDTX), the world’s first special purpose acquisition company focused on investing in the education services and education technology industry, and Meten International Education Group (“Meten”), a leading […]Read More

Junshi Biosciences Announces Full-Year 2019 Financial Results and ...

SHANGHAI, March 30, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced its audited consolidated annual results of the Company and its subsidiaries for the full-year ended December 31, 2019. Financial Highlights (IFRS): Total revenue was RMB775 million, mainly due […]Read More